

2025 Area of Pulmonary Hypertension

Pulmonary Hypertension Areas of Interest

Effective January 2025, the Investigator Studies Program Review Committee (MISP-RC) for Pulmonary Hypertension will accept submissions within our current Areas of Interest (Aols) below. Decisions will be made on the basis of scientific merit and strategic fit within the Aols (which are subject to change).

The following areas are of interest to the Investigator Studies Program Committee:

Pulmonary Hypertension (Sotatercept)

- Characterizing activin signaling pathways through which sotatercept exerts its biological effects and regulates PAH.
- Impact of activin signaling inhibition on physiologic changes in PAH patients on sotatercept.
- Effect of sotatercept in select PAH subgroups (including CTD, age, comorbidities, etc.)/ disease severity (ie. Low risk with high risk imaging features) / background therapies.
- Using real world evidence to study effects of sotatercept in patients with Group 1 PAH.

Submissions will be reviewed and selected by the PH MISP Review Committee.

※申し込みは受け付けますが、研究の開始時期については別途お問合せください。